Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Off-Label Use of Atypical Antipsychotics: An Update

Slide: 34 of 47

Adverse Effects in Elderly Patients: Placebo Comparisons (2 of 3)

A meta-analysis performed for the comparative effectiveness review shows that among elderly patients (65 and older), risperidone treatment is associated with an increased risk of cerebrovascular accidents and cardiovascular adverse events and that olanzapine is associated with an increased risk of cardiovascular adverse events.

Four studies with a total of 1,852 participants examined cerebrovascular accidents associated with risperidone treatment, finding that when compared with placebo, 1 of every 53 patients treated with risperidone experiences a cerebrovascular accident. The strength of evidence in support of this finding is moderate. Six studies with a total of 2,767 participants examined cardiovascular adverse events associated with risperidone treatment, finding that when compared with placebo, 1 of every 34 patients treated with risperidone experiences a cardiovascular adverse event. The strength of evidence in support of this finding is moderate.

Five studies with a total of 1,218 participants examined cardiovascular adverse events associated with olanzapine treatment, finding that when compared with placebo, 1 of every 48 patients treated with olanzapine experiences a cardiovascular adverse event. The strength of evidence in support of this finding is moderate.